

2017 Oncology Pharmacy Specialty Home Study Syllabus for Recertification, Volume 1: Melanoma, Oncology Drug Literature: Biostatistics and Study Design, Multiple Myeloma, and Pediatric Malignancies Learning Objectives

Melanoma

1. Describe the dosing, administration, and toxicity of talimogene laherparepvec (T-VEC) for an appropriate patient.
2. Discuss the characteristics of patients who are most likely to benefit from T-VEC therapy.
3. Explain the pharmacology of T-VEC and how this translates to its unique mechanism of action.

Oncology Drug Literature: Biostatistics and Study Design

1. Evaluate a waterfall plot with respect to its use in a randomized trial.
2. Critique a randomized trial with respect to statistical analyses and waterfall plots.
3. Evaluate and modify educational materials for oncology therapies according to the results of a randomized trial.

Multiple Myeloma

1. Analyze, evaluate, and interpret clinical outcomes data for chemotherapy regimens used for the treatment of multiple myeloma.
2. Use patient-specific clinical data for appropriate therapeutic treatment recommendations in multiple myeloma.
3. Identify and manage potential toxicities associated with chemotherapy agents used in the treatment of multiple myeloma.

Pediatric Malignancies

1. Discuss the pharmacodynamic properties and adverse effects of corticosteroids, including dexamethasone, hydrocortisone, and prednisone.
2. Evaluate the strengths and weaknesses of the crossover clinical trial design.
3. Recommend evidence-based, patient-specific treatment plans for pediatric patients with acute lymphoblastic leukemia receiving dexamethasone therapy.

2017 Oncology Pharmacy Specialty Home Study Syllabus for Recertification, Volume 1: Hematopoietic Stem Cell Transplantation, Oncology Pharmacy Administration, Chronic Leukemias, and Sarcoma Learning Objectives

Hematopoietic Stem Cell Transplantation

1. Determine the role, timing, and conditioning regimen most appropriate for an autologous stem cell transplant in the care of patients with multiple myeloma.
2. Appraise the risk-benefit of maintenance therapies to prevent relapse of multiple myeloma after an autologous stem cell transplant.
3. Evaluate the limitations of the Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.

Oncology Pharmacy Administration

1. Describe the contributing factors to shortages of injectable antineoplastic drugs.
2. Describe the scope of economic issues that result from shortages of injectable antineoplastic drugs.
3. Assess the trends of drug shortages affecting front-line agents for the treatment of breast, colon, and lung cancers.
1. Articulate confounding factors to the authors' conclusions that may limit the number of broad conclusions drawn from the data presented in the paper.

Chronic Leukemias

1. Design and justify principles of treatment and supportive care for patients with chronic lymphocytic leukemia (CLL).
2. Evaluate the outcomes and toxicities of a novel treatment regimen compared with the current standard of care in patients with CLL.

Sarcoma

1. Discuss the role of eribulin in soft tissue sarcomas.
2. Evaluate the outcomes and toxicities of eribulin in patients with soft tissue sarcomas.
3. Apply the results of eribulin to a patient case.